Molecular Oncology
Volume 3, Issue 4 , Pages 321-338 , August 2009

Endocytic proteins in the regulation of nuclear signaling, transcription and tumorigenesis

Received 21 April 2009 ,Revised 1 June 2009 ,Accepted 2 June 2009.

References 

  1. Adams A, Thorn JM, Yamabhai M, Kay BK, O'Bryan JP. Intersectin, an adaptor protein involved in clathrin-mediated endocytosis, activates mitogenic signaling pathways. J. Biol. Chem. 2000;275:27414–27420
  2. Alber F, Dokudovskaya S, Veenhoff LM, Zhang W, Kipper J, Devos D, et al. The molecular architecture of the nuclear pore complex. Nature. 2007;450:695–701
  3. Anupam K, Tusharkant C, Gupta SD, Ranju R. Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis. World J. Gastroenterol. 2006;12:6041–6045
  4. Aramaki Y, Ogawa K, Toh Y, Ito T, Akimitsu N, Hamamoto H, et al. Direct interaction between metastasis-associated protein 1 and endophilin 3. FEBS Lett. 2005;579:3731–3736
  5. Archangelo LF, Glasner J, Krause A, Bohlander SK. The novel CALM interactor CATS influences the subcellular localization of the leukemogenic fusion protein CALM/AF10. Oncogene. 2006;25:4099–4109
  6. Argani P, Lui MY, Couturier J, Bouvier R, Fournet JC, Ladanyi M. A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23). Oncogene. 2003;22:5374–5378
  7. Asao H, Sasaki Y, Arita T, Tanaka N, Endo K, Kasai H, et al. Hrs is associated with STAM, a signal-transducing adaptor molecule. Its suppressive effect on cytokine-induced cell growth. J. Biol. Chem. 1997;272:32785–32791
  8. Bagadi SA, Prasad CP, Srivastava A, Prashad R, Gupta SD, Ralhan R. Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer. Breast Cancer Res. Treat. 2007;104:277–286
  9. Bhattacharyya NP, Banerjee M, Majumder P. Huntington's disease: roles of huntingtin-interacting protein 1 (HIP-1) and its molecular partner HIPPI in the regulation of apoptosis and transcription. FEBS J. 2008;275:4271–4279
  10. Bohlander SK, Muschinsky V, Schrader K, Siebert R, Schlegelberger B, Harder L, et al. Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients. Leukemia. 2000;14:93–99
  11. Boissan M, Wendum D, Arnaud-Dabernat S, Munier A, Debray M, Lascu I, et al. Increased lung metastasis in transgenic NM23-Null/SV40 mice with hepatocellular carcinoma. J. Natl. Cancer Inst. 2005;97:836–845
  12. Bradley SV, Holland EC, Liu GY, Thomas D, Hyun TS, Ross TS. Huntingtin interacting protein 1 is a novel brain tumor marker that associates with epidermal growth factor receptor. Cancer Res. 2007;67:3609–3615
  13. Bradley SV, Smith MR, Hyun TS, Lucas PC, Li L, Antonuk D, et al. Aberrant Huntingtin interacting protein 1 in lymphoid malignancies. Cancer Res. 2007;67:8923–8931
  14. Bridge JA, Kanamori M, Ma Z, Pickering D, Hill DA, Lydiatt W, et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am. J. Pathol. 2001;159:411–415
  15. Buchanan FG, DuBois RN. Emerging roles of β-arrestins. Cell Cycle. 2006;5:2060–2063
  16. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of β-arrestin 1 in the metastatic progression of colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 2006;103:1492–1497
  17. Burgdorf S, Leister P, Scheidtmann KH. TSG101 interacts with apoptosis-antagonizing transcription factor and enhances androgen receptor-mediated transcription by promoting its monoubiquitination. J. Biol. Chem. 2004;279:17524–17534
  18. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J. Clin. Invest. 2007;117:2713–2722
  19. Carlson KM, Vignon C, Bohlander S, Martinez-Climent JA, Le Beau MM, Rowley JD. Identification and molecular characterization of CALM/AF10fusion products in T cell acute lymphoblastic leukemia and acute myeloid leukemia. Leukemia. 2000;14:100–104
  20. Carstens MJ, Krempler A, Triplett AA, Van Lohuizen M, Wagner KU. Cell cycle arrest and cell death are controlled by p53-dependent and p53-independent mechanisms in Tsg101-deficient cells. J. Biol. Chem. 2004;279:35984–35994
  21. Chang MY, Boulden J, Sutanto-Ward E, Duhadaway JB, Soler AP, Muller AJ, et al. Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Res. 2007;67:100–107
  22. Chen W, ten Berge D, Brown J, Ahn S, Hu LA, Miller WE, et al. Dishevelled 2 recruits β-arrestin 2 to mediate Wnt5A-stimulated endocytosis of Frizzled 4. Science. 2003;301:1391–1394
  23. Cho SY, Jeon JW, Lee SH, Park SS. p67 isoform of mouse disabled 2 protein acts as a transcriptional activator during the differentiation of F9 cells. Biochem. J. 2000;352(Pt 3):645–650
  24. Chua HH, Lee HH, Chang SS, Lu CC, Yeh TH, Hsu TY, et al. Role of the TSG101 gene in Epstein–Barr virus late gene transcription. J. Virol. 2007;81:2459–2471
  25. Colaluca IN, Tosoni D, Nuciforo P, Senic-Matuglia F, Galimberti V, Viale G, et al. NUMB controls p53 tumour suppressor activity. Nature. 2008;451:76–80
  26. Curtis CD, Likhite VS, McLeod IX, Yates JR, Nardulli AM. Interaction of the tumor metastasis suppressor nonmetastatic protein 23 homologue H1 and estrogen receptor α alters estrogen-responsive gene expression. Cancer Res. 2007;67:10600–10607
  27. Das M, Scappini E, Martin NP, Wong KA, Dunn S, Chen YJ, et al. Regulation of neuron survival through an intersectin-phosphoinositide 3′-kinase C2beta-AKT pathway. Mol. Cell Biol. 2007;27:7906–7917
  28. Disanza A, Frittoli E, Palamidessi A, Scita G. Endocytosis and spatial restriction of cell signaling. Mol. Oncol. 2009;3:280–296
  29. Diwakar R, Pearson AL, Colville-Nash P, Baines DL, Dockrell ME. Role played by disabled-2 in albumin induced MAP kinase signalling. Biochem. Biophys. Res. Commun. 2008;366:675–680
  30. DuHadaway JB, Lynch FJ, Brisbay S, Bueso-Ramos C, Troncoso P, McDonnell T, et al. Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer. J. Cell Biochem. 2003;88:635–642
  31. DuHadaway JB, Sakamuro D, Ewert DL, Prendergast GC. Bin1 mediates apoptosis by c-Myc in transformed primary cells. Cancer Res. 2001;61:3151–3156
  32. Elliott K, Sakamuro D, Basu A, Du W, Wunner W, Staller P, et al. Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms. Oncogene. 1999;18:3564–3573
  33. Enari M, Ohmori K, Kitabayashi I, Taya Y. Requirement of clathrin heavy chain for p53-mediated transcription. Genes Dev. 2006;20:1087–1099
  34. Fan H, Luttrell LM, Tempel GE, Senn JJ, Halushka PV, Cook JA. Beta-arrestins 1 and 2 differentially regulate LPS-induced signaling and pro-inflammatory gene expression. Mol. Immunol. 2007;44:3092–3099
  35. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell. 2003;112:659–672
  36. Feng Q, Zhang Y. The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev. 2001;15:827–832
  37. Fish KN, Schmid SL, Damke H. Evidence that dynamin-2 functions as a signal-transducing GTPase. J. Cell. Biol. 2000;150:145–154
  38. Fong AM, Premont RT, Richardson RM, Yu YR, Lefkowitz RJ, Patel DD. Defective lymphocyte chemotaxis in beta-arrestin2- and GRK6-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 2002;99:7478–7483
  39. Fuerthauer M, Gonzalez-Gaitan M. Endocytosis, asymmetric cell division, stem cells and cancer: Unus pro omnibus, omnes pro uno. Mol. Oncol. 2009;3:339–353
  40. Gallahan D, Jhappan C, Robinson G, Hennighausen L, Sharp R, Kordon E, et al. Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Res. 1996;56:1775–1785
  41. Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U, Prendergast GC. Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc. Natl. Acad. Sci. U.S.A. 1999;96:9689–9694
  42. Gutmann DH, Haipek CA, Burke SP, Sun CX, Scoles DR, Pulst SM. The NF2 interactor, hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), associates with merlin in the “open” conformation and suppresses cell growth and motility. Hum. Mol. Genet. 2001;10:825–834
  43. Hartsough MT, Steeg PS. Nm23/nucleoside diphosphate kinase in human cancers. J. Bioenerg. Biomembr. 2000;32:301–308
  44. Hittelman AB, Burakov D, Iniguez-Lluhi JA, Freedman LP, Garabedian MJ. Differential regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins. EMBO J. 1999;18:5380–5388
  45. Hocevar BA, Mou F, Rennolds JL, Morris SM, Cooper JA, Howe PH. Regulation of the Wnt signaling pathway by disabled-2 (Dab2). EMBO J. 2003;22:3084–3094
  46. Hocevar BA, Prunier C, Howe PH. Disabled-2 (Dab2) mediates transforming growth factor beta (TGFbeta)-stimulated fibronectin synthesis through TGFbeta-activated kinase 1 and activation of the JNK pathway. J. Biol. Chem. 2005;280:25920–25927
  47. Hocevar BA, Smine A, Xu XX, Howe PH. The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. EMBO J. 2001;20:2789–2801
  48. Huang Y, Friess H, Kleeff J, Esposito I, Zhu Z, Liu S, et al. Doc-2/hDab2 expression is up-regulated in primary pancreatic cancer but reduced in metastasis. Lab. Invest. 2001;81:863–873
  49. Hyman J, Chen H, Di Fiore PP, De Camilli P, Brunger AT. Epsin 1 undergoes nucleocytosolic shuttling and its eps15 interactor NH(2)-terminal homology (ENTH) domain, structurally similar to Armadillo and HEAT repeats, interacts with the transcription factor promyelocytic leukemia Zn(2)+ finger protein (PLZF). J. Cell Biol. 2000;149:537–546
  50. Ishibashi Y, Maita H, Yano M, Koike N, Tamai K, Ariga H, et al. Pim-1 translocates sorting nexin 6/TRAF4-associated factor 2 from cytoplasm to nucleus. FEBS Lett. 2001;506:33–38
  51. Jiang Y, Prunier C, Howe PH. The inhibitory effects of Disabled-2 (Dab2) on Wnt signaling are mediated through Axin. Oncogene. 2008;27:1865–1875
  52. Juven-Gershon T, Shifman O, Unger T, Elkeles A, Haupt Y, Oren M. The Mdm2 oncoprotein interacts with the cell fate regulator Numb. Mol. Cell Biol. 1998;18:3974–3982
  53. Kamura T, Burian D, Khalili H, Schmidt SL, Sato S, Liu WJ, et al. Cloning and characterization of ELL-associated proteins EAP45 and EAP20. A role for yeast EAP-like proteins in regulation of gene expression by glucose. J. Biol. Chem. 2001;276:16528–16533
  54. Kang J, Shi Y, Xiang B, Qu B, Su W, Zhu M, et al. A nuclear function of beta-arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription. Cell. 2005;123:833–847
  55. Kantor JD, McCormick B, Steeg PS, Zetter BR. Inhibition of cell motility after nm23 transfection of human and murine tumor cells. Cancer Res. 1993;53:1971–1973
  56. Karam JA, Shariat SF, Huang HY, Pong RC, Ashfaq R, Shapiro E, et al. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clin. Cancer Res. 2007;13:4400–4406
  57. Kleeff J, Huang Y, Mok SC, Zimmermann A, Friess H, Buchler MW. Down-regulation of DOC-2 in colorectal cancer points to its role as a tumor suppressor in this malignancy. Dis. Colon Rectum. 2002;45:1242–1248
  58. Krishnan KS, Rikhy R, Rao S, Shivalkar M, Mosko M, Narayanan R, et al. Nucleoside diphosphate kinase, a source of GTP, is required for dynamin-dependent synaptic vesicle recycling. Neuron. 2001;30:197–210
  59. Kurten RC, Cadena DL, Gill GN. Enhanced degradation of EGF receptors by a sorting nexin, SNX1. Science. 1996;272:1008–1010
  60. Lanctot C, Cheutin T, Cremer M, Cavalli G, Cremer T. Dynamic genome architecture in the nuclear space: regulation of gene expression in three dimensions. Nat. Rev. Genet. 2007;8:104–115
  61. Lanzetti L, Di Fiore PP. Endocytosis and cancer: an ‘insider’ network with dangerous liaisons. Traffic. 2008;9:2011–2021
  62. Li J, Belogortseva N, Porter D, Park M. Chmp1A functions as a novel tumor suppressor gene in human embryonic kidney and ductal pancreatic tumor cells. Cell Cycle. 2008;7:2886–2893
  63. Li L, Cohen SN. Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell. 1996;85:319–329
  64. Li L, Liao J, Ruland J, Mak TW, Cohen SN. A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. Proc. Natl. Acad. Sci. U.S.A. 2001;98:1619–1624
  65. Liu H, Chen B, Xiong H, Huang QH, Zhang QH, Wang ZG, et al. Functional contribution of EEN to leukemogenic transformation by MLL-EEN fusion protein. Oncogene. 2004;23:3385–3394
  66. Ma L, Pei G. β-Arrestin signaling and regulation of transcription. J. Cell Sci. 2007;120:213–218
  67. Majumder P, Choudhury A, Banerjee M, Lahiri A, Bhattacharyya NP. Interactions of HIPPI, a molecular partner of Huntingtin interacting protein HIP1, with the specific motif present at the putative promoter sequence of the caspase-1, caspase-8 and caspase-10 genes. FEBS J. 2007;274:3886–3899
  68. Miaczynska M, Christoforidis S, Giner A, Shevchenko A, Uttenweiler-Joseph S, Habermann B, et al. APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment. Cell. 2004;116:445–456
  69. Mills IG, Gaughan L, Robson C, Ross T, McCracken S, Kelly J, et al. Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors. J. Cell Biol. 2005;170:191–200
  70. Mishra SK, Keyel PA, Hawryluk MJ, Agostinelli NR, Watkins SC, Traub LM. Disabled-2 exhibits the properties of a cargo-selective endocytic clathrin adaptor. EMBO J. 2002;21:4915–4926
  71. Miura S, Takeshita T, Asao H, Kimura Y, Murata K, Sasaki Y, et al. Hgs (Hrs), a FYVE domain protein, is involved in Smad signaling through cooperation with SARA. Mol. Cell Biol. 2000;20:9346–9355
  72. Mo W, Zhang L, Yang G, Zhai J, Hu Z, Chen Y, et al. Nuclear beta-arrestin1 functions as a scaffold for the dephosphorylation of STAT1 and moderates the antiviral activity of IFN-γ. Mol. Cell. 2008;31:695–707
  73. Mohney RP, Das M, Bivona TG, Hanes R, Adams AG, Philips MR, et al. Intersectin activates Ras but stimulates transcription through an independent pathway involving JNK. J. Biol. Chem. 2003;278:47038–47045
  74. Morita E, Sandrin V, Chung HY, Morham SG, Gygi SP, Rodesch CK, et al. Human ESCRT and ALIX proteins interact with proteins of the midbody and function in cytokinesis. EMBO J. 2007;26:4215–4227
  75. Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat. Rev. Cancer. 2008;8:835–850
  76. Mukherjee A, Veraksa A, Bauer A, Rosse C, Camonis J, Artavanis-Tsakonas S. Regulation of Notch signalling by non-visual β-arrestin. Nat. Cell Biol. 2005;7:1191–1201
  77. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 2007;117:1147–1154
  78. Muromoto R, Sugiyama K, Yamamoto T, Oritani K, Shimoda K, Matsuda T. Physical and functional interactions between Daxx and TSG101. Biochem. Biophys. Res. Commun. 2004;316:827–833
  79. Neuhaus EM, Mashukova A, Barbour J, Wolters D, Hatt H. Novel function of β-arrestin2 in the nucleus of mature spermatozoa. J. Cell Sci. 2006;119:3047–3056
  80. Nguyen LN, Holdren MS, Nguyen AP, Furuya MH, Bianchini M, Levy E, et al. Sorting nexin 1 down-regulation promotes colon tumorigenesis. Clin. Cancer Res. 2006;12:6952–6959
  81. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat. Genet. 2003;33:416–421
  82. Niehof M, Borlak J. EPS15R, TASP1, and PRPF3 are novel disease candidate genes targeted by HNF4α splice variants in hepatocellular carcinomas. Gastroenterology. 2008;134:1191–1202
  83. Oh KB, Stanton MJ, West WW, Todd GL, Wagner KU. Tsg101 is upregulated in a subset of invasive human breast cancers and its targeted overexpression in transgenic mice reveals weak oncogenic properties for mammary cancer initiation. Oncogene. 2007;26:5950–5959
  84. Ohmori K, Endo Y, Yoshida Y, Ohata H, Taya Y, Enari M. Monomeric but not trimeric clathrin heavy chain regulates p53-mediated transcription. Oncogene. 2008;27:2215–2227
  85. Palacios F, Schweitzer JK, Boshans RL, D'Souza-Schorey C. ARF6-GTP recruits Nm23-H1 to facilitate dynamin-mediated endocytosis during adherens junctions disassembly. Nat. Cell Biol. 2002;4:929–936
  86. Passananti C, Floridi A, Fanciulli M. Che-1/AATF, a multivalent adaptor connecting transcriptional regulation, checkpoint control, and apoptosis. Biochem. Cell Biol. 2007;85:477–483
  87. Pece S, Serresi M, Santolini E, Capra M, Hulleman E, Galimberti V, et al. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J. Cell Biol. 2004;167:215–221
  88. Pilecka I, Banach-Orlowska M, Miaczynska M. Nuclear functions of endocytic proteins. Eur. J. Cell Biol. 2007;86:533–547
  89. Pineda-Lucena A, Ho CS, Mao DY, Sheng Y, Laister RC, Muhandiram R, et al. A structure-based model of the c-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants. J. Mol. Biol. 2005;351:182–194
  90. Postel EH, Berberich SJ, Rooney JW, Kaetzel DM. Human NM23/nucleoside diphosphate kinase regulates gene expression through DNA binding to nuclease-hypersensitive transcriptional elements. J. Bioenerg. Biomembr. 2000;32:277–284
  91. Prendergast GC, Muller AJ, Ramalingam A, Chang MY. BAR the door: cancer suppression by amphiphysin-like genes. Biochim. Biophys. Acta. 2009;1795:25–36
  92. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor?. Nat. Rev. Cancer. 2003;3:756–767
  93. Ramalingam A, Duhadaway JB, Sutanto-Ward E, Wang Y, Dinchuk J, Huang M, et al. Bin3 deletion causes cataracts and increased susceptibility to lymphoma during aging. Cancer Res. 2008;68:1683–1690
  94. Ramalingam A, Farmer GE, Stamato TD, Prendergast GC. Bin1 interacts with and restrains the DNA end-binding protein complex Ku. Cell Cycle. 2007;6:1914–1918
  95. Rao DS, Bradley SV, Kumar PD, Hyun TS, Saint-Dic D, Oravecz-Wilson K, et al. Altered receptor trafficking in Huntingtin Interacting Protein 1-transformed cells. Cancer Cell. 2003;3:471–482
  96. Rao DS, Hyun TS, Kumar PD, Mizukami IF, Rubin MA, Lucas PC, et al. Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. J. Clin. Invest. 2002;110:351–360
  97. Rashid S, Pilecka I, Torun A, Olchowik M, Bielinska B, Miaczynska M. Endosomal adaptor proteins APPL1 and APPL2 are novel activators of beta-catenin/TCF-mediated transcription. J. Biol. Chem. 2009;(Epub ahead of print)
  98. Rayner K, Chen YX, Hibbert B, White D, Miller H, Postel EH, et al. Discovery of NM23-H2 as an estrogen receptor beta-associated protein: role in estrogen-induced gene transcription and cell migration. J. Steroid Biochem. Mol. Biol. 2008;108:72–81
  99. Ren G, Vajjhala P, Lee JS, Winsor B, Munn AL. The BAR domain proteins: molding membranes in fission, fusion, and phagy. Microbiol Mol. Biol. Rev. 2006;70:37–120
  100. Rochdi MD, Laroche G, Dupre E, Giguere P, Lebel A, Watier V, et al. Nm23-H2 interacts with a G protein-coupled receptor to regulate its endocytosis through an Rac1-dependent mechanism. J. Biol. Chem. 2004;279:18981–18989
  101. Roscic A, Moller A, Calzado MA, Renner F, Wimmer VC, Gresko E, et al. Phosphorylation-dependent control of Pc2 SUMO E3 ligase activity by its substrate protein HIPK2. Mol. Cell. 2006;24:77–89
  102. Ross TS, Bernard OA, Berger R, Gilliland DG. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor β receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood. 1998;91:4419–4426
  103. Ruland J, Sirard C, Elia A, MacPherson D, Wakeham A, Li L, et al. p53 Accumulation, defective cell proliferation, and early embryonic lethality in mice lacking tsg101. Proc. Natl. Acad. Sci. U.S.A. 2001;98:1859–1864
  104. Saito T, Jones CC, Huang S, Czech MP, Pilch PF. The interaction of Akt with APPL1 is required for insulin-stimulated Glut4 translocation. J. Biol. Chem. 2007;282:32280–32287
  105. Sakamuro D, Elliott KJ, Wechsler-Reya R, Prendergast GC. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat. Genet. 1996;14:69–77
  106. Schmid EM, McMahon HT. Integrating molecular and network biology to decode endocytosis. Nature. 2007;448:883–888
  107. Scoles DR, Huynh DP, Chen MS, Burke SP, Gutmann DH, Pulst SM. The neurofibromatosis 2 tumor suppressor protein interacts with hepatocyte growth factor-regulated tyrosine kinase substrate. Hum. Mol. Genet. 2000;9:1567–1574
  108. Scoles DR, Nguyen VD, Qin Y, Sun CX, Morrison H, Gutmann DH, et al. Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling. Hum. Mol. Genet. 2002;11:3179–3189
  109. Sheng Z, Sun W, Smith E, Cohen C, Xu XX. Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells. Oncogene. 2000;19:4847–4854
  110. Shilatifard A. Identification and purification of the Holo-ELL complex. Evidence for the presence of ELL-associated proteins that suppress the transcriptional inhibitory activity of ELL. J. Biol. Chem. 1998;273:11212–11217
  111. So CW, Lin M, Ayton PM, Chen EH, Cleary ML. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell. 2003;4:99–110
  112. Stauffer DR, Howard TL, Nyun T, Hollenberg SM. CHMP1 is a novel nuclear matrix protein affecting chromatin structure and cell-cycle progression. J. Cell Sci. 2001;114:2383–2393
  113. Stuffers S, Brech A, Stenmark H. ESCRT proteins in physiology and disease. Exp. Cell Res. 2009;315:1619–1626
  114. Sun J, Lin X. β-Arrestin 2 is required for lysophosphatidic acid-induced NF-κB activation. Proc. Natl. Acad. Sci. U.S.A. 2008;105:17085–17090
  115. Sun Z, Pan J, Hope WX, Cohen SN, Balk SP. Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300. Cancer. 1999;86:689–696
  116. Tanaka N, Kyuuma M, Sugamura K. Endosomal sorting complex required for transport proteins in cancer pathogenesis, vesicular transport, and non-endosomal functions. Cancer. Sci. 2008;99:1293–1303
  117. Tong XK, Hussain NK, Adams AG, O'Bryan JP, McPherson PS. Intersectin can regulate the Ras/MAP kinase pathway independent of its role in endocytosis. J. Biol. Chem. 2000;275:29894–29899
  118. Toyoshima M, Tanaka N, Aoki J, Tanaka Y, Murata K, Kyuuma M, et al. Inhibition of tumor growth and metastasis by depletion of vesicular sorting protein Hrs: its regulatory role on E-cadherin and β-catenin. Cancer Res. 2007;67:5162–5171
  119. Tsang HT, Connell JW, Brown SE, Thompson A, Reid E, Sanderson CM. A systematic analysis of human CHMP protein interactions: additional MIT domain-containing proteins bind to multiple components of the human ESCRT III complex. Genomics. 2006;88:333–346
  120. Tseng CP, Ely BD, Li Y, Pong RC, Hsieh JT. Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells. Endocrinology. 1998;139:3542–3553
  121. Tseng CP, Ely BD, Pong RC, Wang Z, Zhou J, Hsieh JT. The role of DOC-2/DAB2 protein phosphorylation in the inhibition of AP-1 activity. An underlying mechanism of its tumor-suppressive function in prostate cancer. J. Biol. Chem. 1999;274:31981–31986
  122. Vaccari T, Bilder D. At the crossroads of polarity, proliferation and apoptosis: the use of Drosophila to unravel the multifaceted role of endocytosis in tumor suppression. Mol. Oncol. 2009;3:354–365
  123. Vecchi M, Di Fiore PP. It's HIP to be a hub: new trends for old-fashioned proteins. J. Cell Biol. 2005;170:169–171
  124. Vecchi M, Polo S, Poupon V, van de Loo JW, Benmerah A, Di Fiore PP. Nucleocytoplasmic shuttling of endocytic proteins. J. Cell Biol. 2001;153:1511–1517
  125. Walker JK, Fong AM, Lawson BL, Savov JD, Patel DD, Schwartz DA, et al. Beta-arrestin-2 regulates the development of allergic asthma. J. Clin. Invest. 2003;112:566–574
  126. Wang P, Wu Y, Ge X, Ma L, Pei G. Subcellular localization of beta-arrestins is determined by their intact N domain and the nuclear export signal at the C terminus. J. Biol. Chem. 2003;278:11648–11653
  127. Wang SC, Makino K, Xia W, Kim JS, Im SA, Peng H, et al. DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway. Oncogene. 2001;20:6960–6964
  128. Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, et al. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J. Biol. Chem. 2002;277:12622–12631
  129. Watanabe M, Yanagi Y, Masuhiro Y, Yano T, Yoshikawa H, Yanagisawa J, et al. A putative tumor suppressor, TSG101, acts as a transcriptional suppressor through its coiled-coil domain. Biochem. Biophys. Res. Commun. 1998;245:900–905
  130. Wechsler-Reya R, Elliott K, Herlyn M, Prendergast GC. The putative tumor suppressor BIN1 is a short-lived nuclear phosphoprotein, the localization of which is altered in malignant cells. Cancer Res. 1997;57:3258–3263
  131. Wechsler-Reya RJ, Elliott KJ, Prendergast GC. A role for the putative tumor suppressor Bin1 in muscle cell differentiation. Mol. Cell Biol. 1998;18:566–575
  132. Xiao K, McClatchy DB, Shukla AK, Zhao Y, Chen M, Shenoy SK, et al. Functional specialization of β-arrestin interactions revealed by proteomic analysis. Proc. Natl. Acad. Sci. U.S.A. 2007;104:12011–12016
  133. Xie W, Li L, Cohen SN. Cell cycle-dependent subcellular localization of the TSG101 protein and mitotic and nuclear abnormalities associated with TSG101 deficiency. Proc. Natl. Acad. Sci. U.S.A. 1998;95:1595–1600
  134. Xu Z, Liang L, Wang H, Li T, Zhao M. HCRP1, a novel gene that is downregulated in hepatocellular carcinoma, encodes a growth-inhibitory protein. Biochem. Biophys. Res. Commun. 2003;311:1057–1066
  135. Yang DH, Smith ER, Cohen C, Wu H, Patriotis C, Godwin AK, et al. Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity. Cancer. 2002;94:2380–2392
  136. Yang L, Lin HK, Altuwaijri S, Xie S, Wang L, Chang C. APPL suppresses androgen receptor transactivation via potentiating Akt activity. J. Biol. Chem. 2003;278:16820–16827
  137. Young TW, Mei FC, Rosen DG, Yang G, Li N, Liu J, et al. Up-regulation of tumor susceptibility gene 101 protein in ovarian carcinomas revealed by proteomics analyses. Mol. Cell Proteomics. 2007;6:294–304
  138. Young TW, Rosen DG, Mei FC, Li N, Liu J, Wang XF, et al. Up-regulation of tumor susceptibility gene 101 conveys poor prognosis through suppression of p21 expression in ovarian cancer. Clin. Cancer Res. 2007;13:3848–3854
  139. Zhong Q, Chen Y, Jones D, Lee WH. Perturbation of TSG101 protein affects cell cycle progression. Cancer Res. 1998;58:2699–2702
  140. Zhou J, Hsieh JT. The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2. J. Biol. Chem. 2001;276:27793–27798
  141. Zhou J, Scholes J, Hsieh JT. Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer. J. Biol. Chem. 2003;278:6936–6941
  142. Zhoul J, Hernandez G, Tu SW, Huang CL, Tseng CP, Hsieh JT. The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. Cancer Res. 2005;65:9906–9913

PII: S1574-7891(09)00081-7

doi: 10.1016/j.molonc.2009.06.001

Molecular Oncology
Volume 3, Issue 4 , Pages 321-338 , August 2009

Article Tools

* Image Usage & Resolution